178 related articles for article (PubMed ID: 16547758)
1. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.
Lobo D; Trinidad A; García-Berrocal JR; Verdaguer JM; Ramírez-Camacho R
Eur Arch Otorhinolaryngol; 2006 Jul; 263(7):622-6. PubMed ID: 16547758
[TBL] [Abstract][Full Text] [Related]
2. Blockage of immune-mediated inner ear damage by etanercept.
Wang X; Truong T; Billings PB; Harris JP; Keithley EM
Otol Neurotol; 2003 Jan; 24(1):52-7. PubMed ID: 12544029
[TBL] [Abstract][Full Text] [Related]
3. Etanercept, a tumour necrosis factor alpha receptor antagonist, and methotrexate in acute sensorineural hearing loss.
Street I; Jobanputra P; Proops DW
J Laryngol Otol; 2006 Dec; 120(12):1064-6. PubMed ID: 17040588
[TBL] [Abstract][Full Text] [Related]
4. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
Van Wijk F; Staecker H; Keithley E; Lefebvre PP
Audiol Neurootol; 2006; 11(6):357-65. PubMed ID: 16988499
[TBL] [Abstract][Full Text] [Related]
5. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study.
Cohen S; Shoup A; Weisman MH; Harris J
Otol Neurotol; 2005 Sep; 26(5):903-7. PubMed ID: 16151336
[TBL] [Abstract][Full Text] [Related]
6. Alternatives to systemic steroid therapy for refractory immune-mediated inner ear disease: A physiopathologic approach.
García-Berrocal JR; Ibáñez A; Rodríguez A; González-García JA; Verdaguer JM; Trinidad A; Ramírez-Camacho R
Eur Arch Otorhinolaryngol; 2006 Nov; 263(11):977-82. PubMed ID: 16802138
[TBL] [Abstract][Full Text] [Related]
7. Therapy of idiopathic sudden sensorineural hearing loss: antiviral treatment of experimental herpes simplex virus infection of the inner ear.
Stokroos RJ; Albers FW; Schirm J
Ann Otol Rhinol Laryngol; 1999 May; 108(5):423-8. PubMed ID: 10335700
[TBL] [Abstract][Full Text] [Related]
8. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.
Matteson EL; Choi HK; Poe DS; Wise C; Lowe VJ; McDonald TJ; Rahman MU
Arthritis Rheum; 2005 Jun; 53(3):337-42. PubMed ID: 15934127
[TBL] [Abstract][Full Text] [Related]
9. Application of a TNF-alpha-inhibitor into the scala tympany after cochlear electrode insertion trauma in guinea pigs: preliminary audiologic results.
Ihler F; Pelz S; Coors M; Matthias C; Canis M
Int J Audiol; 2014 Nov; 53(11):810-6. PubMed ID: 25311100
[TBL] [Abstract][Full Text] [Related]
10. Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss.
Yang GS; Song HT; Keithley EM; Harris JP
Am J Otol; 2000 Jul; 21(4):499-504. PubMed ID: 10912694
[TBL] [Abstract][Full Text] [Related]
11. Juvenile psoriatic arthritis and acquired sensorineural hearing loss in a teenager: is there an association?
Giani T; Simonini G; Lunardi C; Puccetti A; De Martino M; Falcini F
Clin Exp Rheumatol; 2006; 24(3):344-6. PubMed ID: 16870107
[TBL] [Abstract][Full Text] [Related]
12. Current and future use of anti-TNF agents in the treatment of autoimmune, inflammatory disorders.
Calamia KT
Adv Exp Med Biol; 2003; 528():545-9. PubMed ID: 12918761
[No Abstract] [Full Text] [Related]
13. AM-111 reduces hearing loss in a guinea pig model of acute labyrinthitis.
Barkdull GC; Hondarrague Y; Meyer T; Harris JP; Keithley EM
Laryngoscope; 2007 Dec; 117(12):2174-82. PubMed ID: 18322422
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of etanercept in chronic immune-mediated disease.
Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
[TBL] [Abstract][Full Text] [Related]
15. [Experience with an anti-TNFalpha in rheumatology].
Goupille P
Ann Dermatol Venereol; 2005; 132(8-9 Pt 2):4S10-4S12. PubMed ID: 16335347
[No Abstract] [Full Text] [Related]
16. [Anti-TNFalpha therapy in systemic autoimmune and/or inflammatory diseases].
Régent A; Mouthon L
Presse Med; 2009 May; 38(5):761-73. PubMed ID: 19349142
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear.
Trune DR; Kempton JB; Gross ND
Hear Res; 2006 Feb; 212(1-2):22-32. PubMed ID: 16307853
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S
Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431
[TBL] [Abstract][Full Text] [Related]
19. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.
Martínez-Taboada VM; Rodríguez-Valverde V; Carreño L; López-Longo J; Figueroa M; Belzunegui J; Mola EM; Bonilla G
Ann Rheum Dis; 2008 May; 67(5):625-30. PubMed ID: 18086726
[TBL] [Abstract][Full Text] [Related]
20. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
Alty JE; Monaghan TM; Bamford JM
Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
